Component of primary composite endpoint | Pragmatic lifestyle modification | Control lifestyle modification | Incident rate ratio (95% confidence Intervals) | P value |
---|---|---|---|---|
Participants aged ≥ 18 years | n = 876 | n = 938 | ||
Composite | 339 | 387 | 0.93 (0.86–1.03) | 0.11 |
New onset T2DM | 54 | 63 | 0.9 (0.73–1.11) | 0.35 |
New onset IGT | 97 | 105 | 1.01 (0.87–1.17) | 0.89 |
New onset IFG | 88 | 115 | 0.78 (0.67–0.91) | 0.02 |
New onset dysglycaemiaa | 239 | 283 | 0.9 (0.82–1.00) | 0.051 |
Hypertension | 82 | 95 | 0.91 (0.77–1.089) | 0.31 |
Statin therapy | 38 | 45 | 0.89 (0.69–1.15) | 0.39 |
Renal disease events | 0 | 4 | N/A | |
Cardiovascular events | 1 | 0 | N/A | |
Deaths | 1 | 0 | N/A | |
Participants aged < 18 years | n = 850 | n = 875 | ||
Composite | 140 | 174 | 0.83 (0.73–0.94) | 0.004 |
New onset T2DM | 4 | 9 | 0.48 (0.24–0.94) | 0.032 |
New onset IGT | 46 | 63 | 0.74 (0.60–0.90) | 0.009 |
New onset IFG | 58 | 51 | 1.13 (0.93–1.4) | 0.13 |
New onset dysglycaemiaa | 113 | 133 | 0.91 (0.79–1.03) | 0.24 |
Hypertension | 33 | 57 | 0.60 (0.47–0.76) | 0.001 |
Statin therapy | 3 | 1 | 2.89 (0.77–10.7 | 0.11 |
Renal disease events | 2 | 4 | 0.5 (0.19–1.33) | 0.16 |
Cardiovascular events | 0 | 0 | N/A | |
Deaths | 1 | 0 | N/A |